A device built by Marlborough's Boston Scientific has just received clearance from the Centers for Medicare and Medicaid Services (CMS) to be used as a non-pharmacological treatment option for stroke risk reduction.
The rising cost and use of brand name prescription drugs has emerged over the past two years as the one of the newest drivers of health care spending in Massachusetts.
The earnings of Worcester's Hanover Insurance Group soundly beat the expectations of analysts, leading stocks to pop up in trading following the announcement.
The ReWalk exoskeleton system is set to be tested in a 160-person, four-year long, multi-center study by the U.S. Department of Veterans Affairs to evaluate the impact of exoskeleton use in a home or daily life setting.
Gov. Charlie Baker on Thursday proposed to pour almost $1 billion over the next five years into economic development, housing and job training as part of a strategy to maintain strong job growth in the Boston region and revitalize cities and towns still struggling to take advantage of the economic upswing.
A study on the benefits of the ReWalk Robotics exoskeleton found significant improvements in the quality of life for an individual with spinal cord injury using the system.